| P2093 | author name string | Weller M | |
| | Dichgans J | |
| | Roth W | |
| | Wagenknecht B | |
| P2860 | cites work | FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex | Q28283294 |
| | Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines | Q34182237 |
| | Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation | Q34223630 |
| | Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma | Q36079507 |
| | Lethal effect of the anti-Fas antibody in mice | Q36696599 |
| | Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? | Q37364901 |
| | A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma | Q40760111 |
| | Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study | Q40766702 |
| | Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. | Q40959993 |
| | Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest | Q41064243 |
| | Involvement of an ICE-like protease in Fas-mediated apoptosis | Q41347325 |
| | CD95 ligand: lethal weapon against malignant glioma? | Q41740093 |
| | Induction of growth suppression and modification of gene expression in multi‐drug‐resistant human glioblastoma multiforme cells by recombinant human fibroblast and immune interferon | Q42804316 |
| | Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines | Q42813615 |
| | Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation | Q44243498 |
| | Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults | Q48303492 |
| | Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma | Q48459739 |
| | Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study | Q48637015 |
| | Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors | Q48673813 |
| | Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics | Q48778469 |
| | Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. | Q55478434 |
| | Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. | Q55481010 |
| | Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis | Q57623673 |
| | The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain | Q71674757 |
| | Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo | Q71708794 |
| | Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2 | Q71930343 |
| P433 | issue | 1-2 | |
| P304 | page(s) | 121-129 | |
| P577 | publication date | 1998-07-01 | |
| P1433 | published in | Journal of Neuroimmunology | Q15716691 |
| P1476 | title | Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells | |
| P478 | volume | 87 | |